Literature DB >> 11888868

Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma.

Per Lindnér1, Anna Doubrovsky, Peter C A Kam, John F Thompson.   

Abstract

BACKGROUND: Isolated limb perfusion (ILP) with cytotoxic agents is a remarkably effective but complex technique used to treat locally recurrent and metastatic melanoma confined to a limb. Isolated limb infusion (ILI), essentially a low-flow ILP performed without oxygenation via percutaneous catheters, has been developed as a simpler alternative.
METHODS: The outcome in 135 patients treated by ILI was reviewed.
RESULTS: The overall response rate in the treated limb was 85% (complete response [CR] rate 41%, partial response rate 44%). Median response duration response was 16 months (24 months for patients with CR). Median patient survival was 34 months. In those with a CR, the median survival was 42 months. CR rate and survival time decreased with increasing disease stage. Patients aged >70 years had a better overall response than younger patients. On multivariate analysis, factors associated with an improved outcome were a lower stage of disease, a final limb temperature >37.8 degrees C, and a tourniquet time >40 minutes.
CONCLUSIONS: The frequency and duration of responses after ILI were comparable to those achieved by conventional ILP. The ILI technique is particularly useful for older patients who might not be considered suitable for conventional ILP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888868     DOI: 10.1007/bf02557363

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  27 in total

1.  Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.

Authors:  Amanda K Raymond; Georgia M Beasley; Gloria Broadwater; Christina K Augustine; James C Padussis; Ryan Turley; Bercedis Peterson; Hilliard Seigler; Scott K Pruitt; Douglas S Tyler
Journal:  J Am Coll Surg       Date:  2011-04-13       Impact factor: 6.113

Review 2.  Drug resistance and cellular adaptation to tumor acidic pH microenvironment.

Authors:  Jonathan W Wojtkowiak; Daniel Verduzco; Karla J Schramm; Robert J Gillies
Journal:  Mol Pharm       Date:  2011-10-26       Impact factor: 4.939

3.  Isolated limb infusion: Efficacy, toxicity and an evolution in the management of in-transit melanoma.

Authors:  Laura Chin-Lenn; Claire Temple-Oberle; J Gregory McKinnon
Journal:  Plast Surg (Oakv)       Date:  2015       Impact factor: 0.947

4.  Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.

Authors:  Georgia M Beasley; Jonathan C Riboh; Christina K Augustine; Jonathan S Zager; Steven N Hochwald; Stephen R Grobmyer; Bercedis Peterson; Richard Royal; Merrick I Ross; Douglas S Tyler
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

5.  SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.

Authors:  Yoshihiro Tokuhisa; Michael E Lidsky; Hiroaki Toshimitsu; Ryan S Turley; Georgia M Beasley; Tomio Ueno; Ketan Sharma; Christina K Augustine; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2013-11-27       Impact factor: 5.344

Review 6.  Regional therapies for in-transit disease.

Authors:  Paul J Speicher; Claire H Meriwether; Douglas S Tyler
Journal:  Surg Oncol Clin N Am       Date:  2015-01-30       Impact factor: 3.495

7.  Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.

Authors:  Gina Shetty; Georgia M Beasley; Sara Sparks; Michael Barfield; Melanie Masoud; Paul J Mosca; Scott K Pruitt; April K S Salama; Cliburn Chan; Douglas S Tyler; Kent J Weinhold
Journal:  Ann Surg Oncol       Date:  2013-03-02       Impact factor: 5.344

8.  Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?

Authors:  N McMahon; T Y Cheng; G M Beasley; I Spasojevic; W Petros; C K Augustine; P Zipfel; J C Padussis; G Sanders; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2009-01-30       Impact factor: 5.344

9.  Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia.

Authors:  Michael J Carr; James Sun; Hidde M Kroon; John T Miura; Georgia M Beasley; Norma E Farrow; Paul J Mosca; Michael C Lowe; Clara R Farley; Youngchul Kim; Syeda Mahrukh Hussnain Naqvi; Dennis A Kirichenko; Aishwarya Potdar; Hala Daou; Dean Mullen; Jeffrey M Farma; Michael A Henderson; David Speakman; Jonathan Serpell; Keith A Delman; B Mark Smithers; Brendon J Coventry; Douglas S Tyler; John F Thompson; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2020-09-11       Impact factor: 5.344

10.  Is radiotherapy an effective treatment option for recurrent metastatic malignant melanoma? A case report of short-course, large-fraction radiation and a literature review.

Authors:  Abhirami Hallock; Olga Vujovic; Edward Yu
Journal:  Can J Plast Surg       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.